Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
DRAD's Cash to Debt is ranked higher than
97% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. DRAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DRAD' s Cash to Debt Range Over the Past 10 Years
Min: 0.56  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.83
DRAD's Equity to Asset is ranked higher than
83% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. DRAD: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
DRAD' s Equity to Asset Range Over the Past 10 Years
Min: -1.99  Med: 0.81 Max: 0.84
Current: 0.83
-1.99
0.84
Interest Coverage 55.21
DRAD's Interest Coverage is ranked lower than
60% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. DRAD: 55.21 )
Ranked among companies with meaningful Interest Coverage only.
DRAD' s Interest Coverage Range Over the Past 10 Years
Min: 6.44  Med: 64.56 Max: 9999.99
Current: 55.21
6.44
9999.99
F-Score: 5
Z-Score: 4.66
M-Score: 0.23
WACC vs ROIC
20.53%
129.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 5.21
DRAD's Operating margin (%) is ranked higher than
57% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. DRAD: 5.21 )
Ranked among companies with meaningful Operating margin (%) only.
DRAD' s Operating margin (%) Range Over the Past 10 Years
Min: -16.14  Med: -8.01 Max: 4.53
Current: 5.21
-16.14
4.53
Net-margin (%) 36.59
DRAD's Net-margin (%) is ranked higher than
98% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. DRAD: 36.59 )
Ranked among companies with meaningful Net-margin (%) only.
DRAD' s Net-margin (%) Range Over the Past 10 Years
Min: -14.11  Med: -7.38 Max: 4.45
Current: 36.59
-14.11
4.45
ROE (%) 56.90
DRAD's ROE (%) is ranked higher than
99% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. DRAD: 56.90 )
Ranked among companies with meaningful ROE (%) only.
DRAD' s ROE (%) Range Over the Past 10 Years
Min: -14.95  Med: -9.36 Max: 7.5
Current: 56.9
-14.95
7.5
ROA (%) 45.11
DRAD's ROA (%) is ranked higher than
99% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. DRAD: 45.11 )
Ranked among companies with meaningful ROA (%) only.
DRAD' s ROA (%) Range Over the Past 10 Years
Min: -11.98  Med: -7.64 Max: 5.94
Current: 45.11
-11.98
5.94
ROC (Joel Greenblatt) (%) 35.11
DRAD's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. DRAD: 35.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRAD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -77.58  Med: -35.40 Max: 34.95
Current: 35.11
-77.58
34.95
Revenue Growth (3Y)(%) 1.50
DRAD's Revenue Growth (3Y)(%) is ranked lower than
59% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. DRAD: 1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRAD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -90.7  Med: -6.70 Max: 35.4
Current: 1.5
-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

DRAD Guru Trades in Q4 2014

Jim Simons 1,007,133 sh (+8.10%)
» More
Q1 2015

DRAD Guru Trades in Q1 2015

Jim Simons 926,200 sh (-8.04%)
» More
Q2 2015

DRAD Guru Trades in Q2 2015

Jim Simons 926,200 sh (unchged)
» More
Q3 2015

DRAD Guru Trades in Q3 2015

Jim Simons 926,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 4.40
DRAD's P/E(ttm) is ranked higher than
97% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 26.20 vs. DRAD: 4.40 )
Ranked among companies with meaningful P/E(ttm) only.
DRAD' s P/E(ttm) Range Over the Past 10 Years
Min: 3.38  Med: 24.82 Max: 202.11
Current: 4.4
3.38
202.11
PE(NRI) 4.40
DRAD's PE(NRI) is ranked higher than
97% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 25.70 vs. DRAD: 4.40 )
Ranked among companies with meaningful PE(NRI) only.
DRAD' s PE(NRI) Range Over the Past 10 Years
Min: 3.38  Med: 24.64 Max: 192
Current: 4.4
3.38
192
P/B 1.74
DRAD's P/B is ranked higher than
71% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. DRAD: 1.74 )
Ranked among companies with meaningful P/B only.
DRAD' s P/B Range Over the Past 10 Years
Min: 0.19  Med: 1.20 Max: 2.65
Current: 1.74
0.19
2.65
P/S 1.60
DRAD's P/S is ranked higher than
65% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. DRAD: 1.60 )
Ranked among companies with meaningful P/S only.
DRAD' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 0.93 Max: 2.1
Current: 1.6
0.12
2.1
PFCF 32.67
DRAD's PFCF is ranked lower than
51% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 32.67 )
Ranked among companies with meaningful PFCF only.
DRAD' s PFCF Range Over the Past 10 Years
Min: 4.91  Med: 25.37 Max: 353
Current: 32.67
4.91
353
POCF 21.30
DRAD's POCF is ranked lower than
53% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 21.30 )
Ranked among companies with meaningful POCF only.
DRAD' s POCF Range Over the Past 10 Years
Min: 3.48  Med: 19.16 Max: 412
Current: 21.3
3.48
412
EV-to-EBIT 24.00
DRAD's EV-to-EBIT is ranked lower than
52% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.49 vs. DRAD: 24.00 )
Ranked among companies with meaningful EV-to-EBIT only.
DRAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -128.3  Med: -2.40 Max: 215.7
Current: 24
-128.3
215.7
EV-to-EBITDA 13.99
DRAD's EV-to-EBITDA is ranked higher than
60% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. DRAD: 13.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
DRAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.6  Med: -2.90 Max: 161
Current: 13.99
-126.6
161
Current Ratio 3.51
DRAD's Current Ratio is ranked higher than
63% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. DRAD: 3.51 )
Ranked among companies with meaningful Current Ratio only.
DRAD' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 4.61 Max: 5.53
Current: 3.51
1.03
5.53
Quick Ratio 3.07
DRAD's Quick Ratio is ranked higher than
66% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. DRAD: 3.07 )
Ranked among companies with meaningful Quick Ratio only.
DRAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.88  Med: 4.13 Max: 4.82
Current: 3.07
0.88
4.82
Days Inventory 33.43
DRAD's Days Inventory is ranked higher than
91% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. DRAD: 33.43 )
Ranked among companies with meaningful Days Inventory only.
DRAD' s Days Inventory Range Over the Past 10 Years
Min: 31.58  Med: 41.92 Max: 54.41
Current: 33.43
31.58
54.41
Days Sales Outstanding 51.09
DRAD's Days Sales Outstanding is ranked higher than
75% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. DRAD: 51.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.23  Med: 42.24 Max: 48.9
Current: 51.09
38.23
48.9
Days Payable 24.37
DRAD's Days Payable is ranked lower than
84% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. DRAD: 24.37 )
Ranked among companies with meaningful Days Payable only.
DRAD' s Days Payable Range Over the Past 10 Years
Min: 6.32  Med: 14.09 Max: 18.25
Current: 24.37
6.32
18.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.08
DRAD's Dividend Yield is ranked higher than
90% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.72 vs. DRAD: 4.08 )
Ranked among companies with meaningful Dividend Yield only.
DRAD' s Dividend Yield Range Over the Past 10 Years
Min: 1.3  Med: 4.42 Max: 5.45
Current: 4.08
1.3
5.45
Dividend Payout 0.18
DRAD's Dividend Payout is ranked higher than
89% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 0.34 vs. DRAD: 0.18 )
Ranked among companies with meaningful Dividend Payout only.
DRAD' s Dividend Payout Range Over the Past 10 Years
Min: 0.05  Med: 1.22 Max: 1.28
Current: 0.18
0.05
1.28
Forward Dividend Yield 4.08
DRAD's Forward Dividend Yield is ranked higher than
92% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. DRAD: 4.08 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.09
DRAD's Yield on cost (5-Year) is ranked higher than
83% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. DRAD: 4.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DRAD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.3  Med: 4.42 Max: 5.45
Current: 4.09
1.3
5.45
3-Year Average Share Buyback Ratio 0.30
DRAD's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: -4.30 vs. DRAD: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1314  Med: -0.95 Max: 0.3
Current: 0.3
-1314
0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.89
DRAD's Price/Net Cash is ranked higher than
56% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 12.77 vs. DRAD: 10.89 )
Ranked among companies with meaningful Price/Net Cash only.
DRAD' s Price/Net Cash Range Over the Past 10 Years
Min: 0.68  Med: 2.63 Max: 8.31
Current: 10.89
0.68
8.31
Price/Net Current Asset Value 4.05
DRAD's Price/Net Current Asset Value is ranked higher than
67% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. DRAD: 4.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRAD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.33  Med: 1.69 Max: 3.72
Current: 4.05
0.33
3.72
Price/Tangible Book 1.97
DRAD's Price/Tangible Book is ranked higher than
75% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 3.79 vs. DRAD: 1.97 )
Ranked among companies with meaningful Price/Tangible Book only.
DRAD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.23  Med: 1.33 Max: 3.01
Current: 1.97
0.23
3.01
Price/Projected FCF 1.93
DRAD's Price/Projected FCF is ranked higher than
50% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. DRAD: 1.93 )
Ranked among companies with meaningful Price/Projected FCF only.
DRAD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 2.10 Max: 114
Current: 1.93
0.98
114
Price/Median PS Value 1.72
DRAD's Price/Median PS Value is ranked lower than
85% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. DRAD: 1.72 )
Ranked among companies with meaningful Price/Median PS Value only.
DRAD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 0.95 Max: 2.12
Current: 1.72
0.02
2.12
Price/Graham Number 0.62
DRAD's Price/Graham Number is ranked higher than
87% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. DRAD: 0.62 )
Ranked among companies with meaningful Price/Graham Number only.
DRAD' s Price/Graham Number Range Over the Past 10 Years
Min: 0.47  Med: 1.69 Max: 4.16
Current: 0.62
0.47
4.16
Earnings Yield (Greenblatt) (%) 4.20
DRAD's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. DRAD: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRAD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 5.25 Max: 475
Current: 4.2
0.5
475

More Statistics

Revenue(Mil) $59
EPS $ 1.11
Beta2.49
Short Percentage of Float0.28%
52-Week Range $3.50 - 6.92
Shares Outstanding(Mil)19.42

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FDV.Germany,
Digirad Corp was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The business is organized into two reportable segments: Digirad Imaging Solutions (DIS) and Diagnostic Imaging. It is a provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through Digirad Imaging Solutions ("DIS") business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging segment. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. The Company sells a line of nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its product Ergo large-field-of-view imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women's health centers, and cancer centers. Its Cardius XACT SPECT/CT system features a triple-head design and a low dose volume CT attenuation correction methodology, making it possible to perform studies faster with greater interpretation diagnostic confidence. It uses variety of materials, metals and mechanical and electrical components for production of its products. The Company maintain two sales organizations, which operate independently but in cooperation with each other: Diagnostic Imaging sales and DIS sales. The Company's operations comply with an array of federal and state laws and regulations.
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 

More From Other Websites
Digirad Corporation Announces Quarterly Dividend of $0.05 Per Share Feb 01 2016
Digirad Corporation Announces Quarterly Dividend of $0.05 Per Share Feb 01 2016
What is Lending Momentum to Equity Market - Consensus Reports on Titan International, Digirad,... Jan 28 2016
DIGIRAD CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 21 2016
DIGIRAD CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jan 07 2016
Edited Transcript of DRAD earnings conference call or presentation 30-Oct-15 3:00pm GMT Jan 05 2016
Digirad Corporation Announces Closing of DMS Health Technologies Acquisition and Associated... Jan 05 2016
Digirad Corporation Announces Closing of DMS Health Technologies Acquisition and Associated... Jan 05 2016
DIGIRAD (DRAD) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Digirad Corporation For... Dec 23 2015
How it All Plays Out - Analyst Notes on VimpelCom, Digirad, Compania de Minas Buenaventura and... Dec 23 2015
New Strong Buy Stocks for December 11th Dec 11 2015
DIGIRAD CORP Financials Dec 08 2015
Is Digirad Corporation (DRAD) A Good Stock To Buy? Nov 23 2015
Digirad Corporation to Present at the LD Micro Main Event on December 2, 2015 Nov 18 2015
Digirad Corporation to Present at the LD Micro Main Event on December 2, 2015 Nov 18 2015
Allscripts Q3 Earnings Beat, Revenues Miss by a Whisker Nov 06 2015
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report Nov 02 2015
Omnicell Misses Q3 Earnings, Revenues; Lowers Top-Line View Nov 02 2015
Digirad Corp Earnings Call scheduled for 11:00 am ET today Oct 30 2015
Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September... Oct 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK